EVT has been the topic of a number of other reports. Berenberg Bank set a €13.00 ($15.48) price objective on Evotec and gave the company a neutral rating in a research note on Thursday, August 10th. Oddo Bhf set a €20.00 ($23.81) price objective on Evotec and gave the company a buy rating in a research note on Wednesday, November 29th. Finally, Oddo Securities set a €14.00 ($16.67) price objective on Evotec and gave the company a neutral rating in a research note on Friday, August 11th.
Evotec (EVT) opened at €11.63 ($13.85) on Tuesday. Evotec has a one year low of €5.93 ($7.06) and a one year high of €22.50 ($26.79).
COPYRIGHT VIOLATION NOTICE: “Evotec (EVT) Given a €17.00 Price Target by Deutsche Bank Analysts” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/12/06/evotec-evt-given-a-17-00-price-target-by-deutsche-bank-analysts.html.
Evotec Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.